All News

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

From 1990 to 2016, the rate of deaths due to adverse effects of medical treatment decreased 21.4% in the United States.

One lot of irbesartan and 7 lots of irbesartan and hydrochlorothiazide (HCTZ) combination tablets distributed by Solco Healthcare, a Prinston Pharmaceutical subsidiary are affected.

Students can set themselves apart during rotations, with these tips from a preceptor.

Officials with the FDA have approved Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer and HER2 overexpressing gastric cancer.

Officials with the FDA today approved Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar trastuzumab referencing Herceptin.

Recommendations outline the efficacy of different types of therapies, dosing regimens, and routes for patients with mild-to-moderate ulcerative colitis.

A look at last week's top stories in the world of pharmacy.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Understanding the rate of hepatitis C infection is critical for making strategies to reduce the disease burden among specific populations.

Average total drug spending per hospital admission increased by 18.5% between FY2015 and FY2017.

Atezolizumab (Tecentriq) plus chemotherapy significantly extended survival in patients with metastatic non-squamous non-small cell lung cancer.

The target action date for the FDA’s decision on caplacizumab (Cablivi) is February 6, 2019.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Ocrelizumab found more effective in reducing the risk of 12-week confirmed disability progression compared with 10 other treatments for relapsing multiple sclerosis.

Officials with the FDA today approved the first generic version of vigabatrin 500-mg tablets, which is also sold under the brand name Sabril, a medication used to treat complex partial seizures.

Vigabatrin, which is also sold under the brand name Sabril, is used to treat complex partial seizures in adult and pediatric patients.

This interoperable standard created to exchange information across the health care spectrum is gaining traction across the country.

BeiGene’s investigational Bruton’s tyrosine kinase (BTK) inhibitor, zanubrutinib (BGB-3111), has been granted Breakthrough Therapy designation by the FDA for the treatment of adults with mantle cell lymphoma (MCL) who have received at least 1 prior therapy.

Zanubrutinib (BGB-3111) is being investigated for the treatment of various B-cell malignancies, including mantle cell lymphoma.

Offering screening and referrals for mental health and peer support services can improve HIV outcomes in American Indian and Alaska Native patients.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Measles outbreaks are on the rise globally, and it is considered a public health crisis.

The committee is seeking detailed information and documents about some pharmaceutical companies' prescription drug pricing practices.

Application of core area methodology can help identify new hepatitis C cases and outbreaks and improve testing and treatment.